OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Results Highlights:- Revenue hit record high of US$164.1 million, up 6.6% year-on-year.- Sales volume reached 1.7 million units, of which 1.5 million units were proprietary products, showing an increase of 4.8% year-on-year.- Gross profit increased by 7.5% to US$114.5 million, with gross profit margin improving to 69.8%; profit for the year attributable to owners of the Company was US$39.7 million.- The Board proposed a final dividend of HK10 cents per share, representing a dividend payout ratio of 26.7%.- The Group maintained a sound financial position with cash and bank balances of US$248.6 million at year-end to support merger and acquisition initiatives.- Fueled by newly acquired distributors in Indonesia and South Korea, along with organic growth in direct sales, APAC market revenue grew 43.7% year-on-year, while the US and the PRC markets showed signs of recovery in the second half of 2024.- The Group registered products of eucatech AG, a German company acquired in November 2023, in the Czech Republic, Italy, Malaysia, Saudi Arabia, Spain, Switzerland, UAE, and Vietnam.HONG KONG, Mar 7, 2025 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“Orbu...
